The looming threat of bedaquiline resistance in tuberculosis

Multidrug- and rifampicin-resistant tuberculosis (MDR-/RR-TB) have evolved into a global public health crisis. In late 2019, the World Health Organization (WHO) issued a rapid communication [1] advising national TB programmes to phase out the injectable-containing shorter regimen. WHO indicated that the preferred treatment option is a shorter, all-oral, bedaquiline-containing regimen and emphasised that "access to rapid drug susceptibility testing, especially for ruling out fluoroquinolone resistance, is required" before starting the bedaquiline-containing shorter regimen [1].

Source: European Respiratory Journal - June 3, 2020 Category: Respiratory Medicine Authors: Chiang, C.-Y., Trebucq, A., Piubello, A., Rieder, H. L., Schwoebel, V., Van Deun, A. Tags: Original Articles: Correspondence Source Type: research